Tavaborole

Tavaborole
Clinical data
Trade names	Kerydin
Other names	AN2690
AHFS/Drugs.com	Monograph
MedlinePlus	a614049
Routes of; administration	Topical
ATC code	D01AE24 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-Fluoro-2,1-benzoxaborol-1(3H)-ol;
CAS Number	174671-46-6;
PubChem CID	11499245;
DrugBank	DB09041;
ChemSpider	9674047;
UNII	K124A4EUQ3;
KEGG	D10169;
CompTox Dashboard (EPA)	DTXSID00169888 ;
ECHA InfoCard	100.218.130
Chemical and physical data
Formula	C7H6BFO2
Molar mass	151.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES B1(C2=C(CO1)C=C(C=C2)F)O;
	InChI InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2; Key:LFQDNHWZDQTITF-UHFFFAOYSA-N;

Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.”^[1] Tavaborole was approved by the US FDA in July 2014.^[2] The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.

^ Cite error: The named reference :0 was invoked but never defined (see the help page).
^ "FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails". Market Watch. July 8, 2014.

[:0-1] Cite error: The named reference :0 was invoked but never defined (see the help page).

[2] "FDA Approves Anacor Pharmaceuticals' KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails". Market Watch. July 8, 2014.

[1]

[2]